Central venulitis in the allograft liver a clinicopathologic study

Athanassios C. Tsamandas, Ashok B. Jain, Evangelos S. Felekouras, John J. Fung, Anthony J. Demetris, Randall G. Lee

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Background. Central venulitis denotes a histologic lesion of the allograft liver characterized by perivenular and subendothelial mononuclear inflammation of the terminal hepatic venules associated with varying degrees of perivenular hepatocyte dropout. Although this lesion has generally been considered a manifestation of acute rejection, some have suggested that it instead represents tacrolimus hepatotoxicity. Methods. We therefore compared the clinicopathologic features of 30 episodes of isolated central venulitis with 22 episodes of combined central venulitis and typical portal acute rejection occurring in 27 patients. Nineteen of the patients received tacrolimus and eight received cyclosporine as primary immunosuppression. Results. No significant differences were found between the two groups, except that isolated central venulitis more often displayed a mild inflammatory component (P=0.007) with small lymphocytes as the predominant cell type (P=0.002). None of the patients had tacrolimus or cyclosporine levels that exceeded the therapeutic range, and none had other clinical evidence of drug toxicity. Usual antirejection therapy was instituted in all but two episodes; response was evident in 93% (28 of 30) of the isolated central venulitis and 86% (19 of 22) of the central venulitis-portal acute rejection group, with histologic regression documented in all follow-up specimens (four and five, respectively). Due to persistent central venulitis, two cyclosporine patients were switched to tacrolimus, with prompt resolution. Conclusions. These findings are inconsistent with the concept that central venulitis represents drug toxicity and indicate instead that it is a form of acute allograft rejection.

Original languageEnglish (US)
Pages (from-to)252-257
Number of pages6
JournalTransplantation
Volume64
Issue number2
DOIs
StatePublished - Jul 27 1997

Fingerprint

Tacrolimus
Allografts
Cyclosporine
Liver
Drug-Related Side Effects and Adverse Reactions
Immunosuppression
Venules
Hepatocytes
Lymphocytes
Inflammation
Therapeutics

All Science Journal Classification (ASJC) codes

  • Transplantation

Cite this

Tsamandas, A. C., Jain, A. B., Felekouras, E. S., Fung, J. J., Demetris, A. J., & Lee, R. G. (1997). Central venulitis in the allograft liver a clinicopathologic study. Transplantation, 64(2), 252-257. https://doi.org/10.1097/00007890-199707270-00013
Tsamandas, Athanassios C. ; Jain, Ashok B. ; Felekouras, Evangelos S. ; Fung, John J. ; Demetris, Anthony J. ; Lee, Randall G. / Central venulitis in the allograft liver a clinicopathologic study. In: Transplantation. 1997 ; Vol. 64, No. 2. pp. 252-257.
@article{f3bb27741d9e4ecea58be10e77195b1a,
title = "Central venulitis in the allograft liver a clinicopathologic study",
abstract = "Background. Central venulitis denotes a histologic lesion of the allograft liver characterized by perivenular and subendothelial mononuclear inflammation of the terminal hepatic venules associated with varying degrees of perivenular hepatocyte dropout. Although this lesion has generally been considered a manifestation of acute rejection, some have suggested that it instead represents tacrolimus hepatotoxicity. Methods. We therefore compared the clinicopathologic features of 30 episodes of isolated central venulitis with 22 episodes of combined central venulitis and typical portal acute rejection occurring in 27 patients. Nineteen of the patients received tacrolimus and eight received cyclosporine as primary immunosuppression. Results. No significant differences were found between the two groups, except that isolated central venulitis more often displayed a mild inflammatory component (P=0.007) with small lymphocytes as the predominant cell type (P=0.002). None of the patients had tacrolimus or cyclosporine levels that exceeded the therapeutic range, and none had other clinical evidence of drug toxicity. Usual antirejection therapy was instituted in all but two episodes; response was evident in 93{\%} (28 of 30) of the isolated central venulitis and 86{\%} (19 of 22) of the central venulitis-portal acute rejection group, with histologic regression documented in all follow-up specimens (four and five, respectively). Due to persistent central venulitis, two cyclosporine patients were switched to tacrolimus, with prompt resolution. Conclusions. These findings are inconsistent with the concept that central venulitis represents drug toxicity and indicate instead that it is a form of acute allograft rejection.",
author = "Tsamandas, {Athanassios C.} and Jain, {Ashok B.} and Felekouras, {Evangelos S.} and Fung, {John J.} and Demetris, {Anthony J.} and Lee, {Randall G.}",
year = "1997",
month = "7",
day = "27",
doi = "10.1097/00007890-199707270-00013",
language = "English (US)",
volume = "64",
pages = "252--257",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Tsamandas, AC, Jain, AB, Felekouras, ES, Fung, JJ, Demetris, AJ & Lee, RG 1997, 'Central venulitis in the allograft liver a clinicopathologic study', Transplantation, vol. 64, no. 2, pp. 252-257. https://doi.org/10.1097/00007890-199707270-00013

Central venulitis in the allograft liver a clinicopathologic study. / Tsamandas, Athanassios C.; Jain, Ashok B.; Felekouras, Evangelos S.; Fung, John J.; Demetris, Anthony J.; Lee, Randall G.

In: Transplantation, Vol. 64, No. 2, 27.07.1997, p. 252-257.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Central venulitis in the allograft liver a clinicopathologic study

AU - Tsamandas, Athanassios C.

AU - Jain, Ashok B.

AU - Felekouras, Evangelos S.

AU - Fung, John J.

AU - Demetris, Anthony J.

AU - Lee, Randall G.

PY - 1997/7/27

Y1 - 1997/7/27

N2 - Background. Central venulitis denotes a histologic lesion of the allograft liver characterized by perivenular and subendothelial mononuclear inflammation of the terminal hepatic venules associated with varying degrees of perivenular hepatocyte dropout. Although this lesion has generally been considered a manifestation of acute rejection, some have suggested that it instead represents tacrolimus hepatotoxicity. Methods. We therefore compared the clinicopathologic features of 30 episodes of isolated central venulitis with 22 episodes of combined central venulitis and typical portal acute rejection occurring in 27 patients. Nineteen of the patients received tacrolimus and eight received cyclosporine as primary immunosuppression. Results. No significant differences were found between the two groups, except that isolated central venulitis more often displayed a mild inflammatory component (P=0.007) with small lymphocytes as the predominant cell type (P=0.002). None of the patients had tacrolimus or cyclosporine levels that exceeded the therapeutic range, and none had other clinical evidence of drug toxicity. Usual antirejection therapy was instituted in all but two episodes; response was evident in 93% (28 of 30) of the isolated central venulitis and 86% (19 of 22) of the central venulitis-portal acute rejection group, with histologic regression documented in all follow-up specimens (four and five, respectively). Due to persistent central venulitis, two cyclosporine patients were switched to tacrolimus, with prompt resolution. Conclusions. These findings are inconsistent with the concept that central venulitis represents drug toxicity and indicate instead that it is a form of acute allograft rejection.

AB - Background. Central venulitis denotes a histologic lesion of the allograft liver characterized by perivenular and subendothelial mononuclear inflammation of the terminal hepatic venules associated with varying degrees of perivenular hepatocyte dropout. Although this lesion has generally been considered a manifestation of acute rejection, some have suggested that it instead represents tacrolimus hepatotoxicity. Methods. We therefore compared the clinicopathologic features of 30 episodes of isolated central venulitis with 22 episodes of combined central venulitis and typical portal acute rejection occurring in 27 patients. Nineteen of the patients received tacrolimus and eight received cyclosporine as primary immunosuppression. Results. No significant differences were found between the two groups, except that isolated central venulitis more often displayed a mild inflammatory component (P=0.007) with small lymphocytes as the predominant cell type (P=0.002). None of the patients had tacrolimus or cyclosporine levels that exceeded the therapeutic range, and none had other clinical evidence of drug toxicity. Usual antirejection therapy was instituted in all but two episodes; response was evident in 93% (28 of 30) of the isolated central venulitis and 86% (19 of 22) of the central venulitis-portal acute rejection group, with histologic regression documented in all follow-up specimens (four and five, respectively). Due to persistent central venulitis, two cyclosporine patients were switched to tacrolimus, with prompt resolution. Conclusions. These findings are inconsistent with the concept that central venulitis represents drug toxicity and indicate instead that it is a form of acute allograft rejection.

UR - http://www.scopus.com/inward/record.url?scp=0030761465&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030761465&partnerID=8YFLogxK

U2 - 10.1097/00007890-199707270-00013

DO - 10.1097/00007890-199707270-00013

M3 - Article

C2 - 9256183

AN - SCOPUS:0030761465

VL - 64

SP - 252

EP - 257

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -